GeNeuro (FRA:GEM) Valuation Rank

View and export this data going back to 2016. Start your Free Trial

What is GeNeuro Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GeNeuro Valuation Rank Related Terms

Thank you for viewing the detailed overview of GeNeuro's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GeNeuro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeNeuro SA (FRA:GEM) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

GNRO:France

Address

3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.geneuro.com

GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).